JewishStatusOpen the app

FrontRow · Jul 31, 2026

FrontRow — photo status

Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo. While the experimental medicine, ziltivekimab, did show some biological effect, it didn’t translate into a statistically meaningful reduction in MACE, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke, for patients with certain diseases, Novo said in a statement on Friday. “While ziltivekimab did not achieve the MACE benefit we had hoped for, this does not change our strategic commitment to cardiovascular disease,” chief scientific officer Martin Holst Lange said. Copenhagen-listed shares were last seen down 7.4% while its American depositary receipts were 8.6% lower in premarket trading. The missed endpoint is the latest blow to the Danish drugmaker, which is racing to restore investor confidence in its pipeline and ability to execute, especially in the challenging U.S. market.

Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo. While the experimental medicine, ziltivekimab, did show some biological effect, it didn’t translate into a statistically meaningful reduction in MACE, defined as cardiovascular death, non-fatal heart attack or non-fatal stroke, for patients with certain diseases, Novo said in a statement on Friday. “While ziltivekimab did not achieve the MACE benefit we had hoped for, this does not change our strategic commitment to cardiovascular disease,” chief scientific officer Martin Holst Lange said. Copenhagen-listed shares were last seen down 7.4% while its American depositary receipts were 8.6% lower in premarket trading. The missed endpoint is the latest blow to the Danish drugmaker, which is racing to restore investor confidence in its pipeline and ability to execute, especially in the challenging U.S. market.

Watch in the app All of FrontRow's statuses

More from FrontRow